For metastatic pancreatic cancer, is there a role for maintenance chemotherapy if patient has stable disease at the end of 12 cycles of dose reduced modified FOLFIRINOX?

Although the original FOLFIRINOX data (Conroy, NEJM, 2011) evaluated efficacy of a six-month course of treatment in patients with metastatic pancreatic cancer, few of us would feel comfortable discontinuing chemotherapy entirely for these patients at the end of a six month period. In the absence of ...